SPARC inversely correlated with BM PC infiltration, ISS staging, and ECOG performance of the MM patients, and in vitro addition of the SPARC-producing FDCs to lymphocytes globally inhibited the expression of several oncogenes associated with malignant transformation of PCs. This evidence concerns the gene SPARC and Miyoshi myopathy.